A detailed history of Royal Bank Of Canada transactions in Celldex Therapeutics, Inc. stock. As of the latest transaction made, Royal Bank Of Canada holds 7,753 shares of CLDX stock, worth $216,231. This represents 0.0% of its overall portfolio holdings.

Number of Shares
7,753
Previous 6,626 17.01%
Holding current value
$216,231
Previous $245,000 7.35%
% of portfolio
0.0%
Previous 0.0%

Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$32.06 - $44.56 $36,131 - $50,219
1,127 Added 17.01%
7,753 $263,000
Q2 2024

Aug 14, 2024

BUY
$32.76 - $42.56 $155,773 - $202,372
4,755 Added 254.14%
6,626 $245,000
Q1 2024

Nov 05, 2024

SELL
$35.22 - $51.88 $167,471 - $246,689
-4,755 Reduced 71.76%
1,871 $78,000
Q1 2024

May 15, 2024

SELL
$35.22 - $51.88 $461,875 - $680,354
-13,114 Reduced 87.51%
1,871 $78,000
Q4 2023

Feb 14, 2024

BUY
$22.61 - $40.65 $163,176 - $293,371
7,217 Added 92.91%
14,985 $594,000
Q3 2023

Nov 14, 2023

BUY
$25.45 - $37.46 $69,962 - $102,977
2,749 Added 54.77%
7,768 $213,000
Q2 2023

Aug 14, 2023

BUY
$30.29 - $38.28 $72,908 - $92,139
2,407 Added 92.15%
5,019 $170,000
Q1 2023

May 15, 2023

SELL
$34.78 - $47.43 $96,305 - $131,333
-2,769 Reduced 51.46%
2,612 $93,000
Q4 2022

Feb 14, 2023

BUY
$27.78 - $45.38 $133,010 - $217,279
4,788 Added 807.42%
5,381 $239,000
Q3 2022

Nov 14, 2022

BUY
$22.7 - $37.57 $6,605 - $10,932
291 Added 96.36%
593 $17,000
Q2 2022

Aug 15, 2022

SELL
$20.5 - $37.33 $51,803 - $94,332
-2,527 Reduced 89.32%
302 $8,000
Q1 2022

May 16, 2022

SELL
$27.64 - $39.32 $185,602 - $264,033
-6,715 Reduced 70.36%
2,829 $96,000
Q4 2021

Feb 14, 2022

BUY
$35.68 - $56.27 $155,457 - $245,168
4,357 Added 84.0%
9,544 $368,000
Q3 2021

Nov 15, 2021

BUY
$28.95 - $55.99 $72,461 - $140,142
2,503 Added 93.26%
5,187 $280,000
Q2 2021

Aug 16, 2021

BUY
$20.71 - $35.37 $55,585 - $94,933
2,684 New
2,684 $90,000

Others Institutions Holding CLDX

About Celldex Therapeutics, Inc.


  • Ticker CLDX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 46,772,400
  • Market Cap $1.3B
  • Description
  • Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory diseases and various forms of cancer. The company's clinical development programs CDX-01...
More about CLDX
Track This Portfolio

Track Royal Bank Of Canada Portfolio

Follow Royal Bank Of Canada and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Royal Bank Of Canada, based on Form 13F filings with the SEC.

News

Stay updated on Royal Bank Of Canada with notifications on news.